Glasdegib is indicated, in combination with LDAC (low-dose cytarabine), for the treatment of newly diagnosed de novo or secondary acute myeloid leukaemia in adult patients who are not candidates for standard induction chemotherapy.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||07/09/2020|
|Rapid review completed||09/10/2020|
|Rapid Review outcome||Reimbursement is not recommended at this time, due to a lack of evaluable evidence*.|
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.